Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06099886 · ClinicalTrials.gov registry record · Phase 1
Repurposing Lithium for Parkinson's Disease
A Phase 1 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT06099886 is a Phase 1 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 15 participants.
The verdict
NCT06099886, a Phase 1 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.
Interventions
- DIETARY_SUPPLEMENT Lithium aspartate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-10-12 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06099886
The ClinicalTrials.gov registry entry for NCT06099886 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lithium aspartate is the first listed.
NCT06099886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06099886 about?
NCT06099886 is a clinical study titled "Repurposing Lithium for Parkinson's Disease". This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.
What is the current status of trial NCT06099886?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-10-12. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT06099886?
The interventions under investigation include: Lithium aspartate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06099886?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.